Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.49 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17541458 | 0.99 | OGA (0.54) | OGAPARP1TNK2TNK1CDC7 | |
| SCHEMBL16982078 | 0.85 | OGA (0.59) | OGAPARP1TNK2TNK1CDC7 | |
| SCHEMBL16113724 | 0.85 | OGA (0.49) | OGAPARP1TNK2TNK1CDC7 | |
| SCHEMBL4092990 | 0.85 | CRBN (0.55) | CYP1A2CYP2C18CYP2C19KCNH2SNCA | |
| SCHEMBL30908402 | 0.84 | OGA (0.55) | OGAPARP1TNK2TNK1CDC7 | |
| SCHEMBL3787851 | 0.83 | OGA (0.57) | OGAPARP1TNK2TNK1CDC7 | |
| SCHEMBL2297207 | 0.82 | OGA (0.48) | OGAPARP1TNK2TNK1CDC7 | |
| Hydrochloric Acid SCHEMBL2831916 | 0.81 | HDAC2 (0.45) | OGACYP1A2CYP2C18CYP2C19KCNH2 | |
| SCHEMBL31281641 | 0.81 | HRH3 (0.53) | OGAPARP1TNK2TNK1CDC7 | |
| SCHEMBL3159022 | 0.80 | ALDH1A1 (0.39) | OGAPARP1TNK2TNK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591327-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2023-02-28 | — | — | US | disclosed |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-29 | — | — | US | disclosed |
| EP-3186243-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-11046712-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2021-06-29 | — | — | US | disclosed |
| EP-3419976-B1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2021-04-07 | — | — | EP | disclosed |
| US-20200385375-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2020-12-10 | — | — | US | disclosed |
| US-10336775-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2019-07-02 | — | — | US | disclosed |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2017-10-19 | — | — | US | disclosed |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2017-10-19 | — | — | US | disclosed |
| WO-2017144637-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2016030443-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2016-03-03 | — | — | WO | disclosed |
| US-7300939-B2 | Substituted 1-propiolylpiperazine compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2007-11-27 | — | — | US | disclosed |
| US-20070112011-A1 | Substituted 1-propiolylpiperazine compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| EP-1755601-A2 | INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050250784-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-11-10 | — | — | US | disclosed |
| WO-2005086898-A2 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050197336-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385375-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | DNPEP, GAA, SLC30A5 | OGA 452/4885PARP1 1736/4885TNK2 3791/4885 |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | OGA 77/4885PARP1 1179/4885TNK2 2711/4885 |
| US-11591327-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | OGA 452/4885PARP1 1736/4885TNK2 3791/4885 |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | OGA 77/4885PARP1 1179/4885TNK2 2711/4885 |
| US-20050197336-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | OGA 866/4885PARP1 203/4885TNK2 362/4885 |
| US-10336775-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | OGA 77/4885PARP1 1179/4885TNK2 2711/4885 |
| US-20050250784-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | OGA 866/4885PARP1 203/4885TNK2 362/4885 |
| US-20070112011-A1 | Substituted 1-propiolylpiperazine compounds, their preparation and use | GRM5, GRIK5, GRM1 | OGA 4512/4885PARP1 4041/4885TNK2 1342/4885 |
| US-11046712-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | OGA 77/4885PARP1 1179/4885TNK2 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.